PPT-Aflibercept for neovascular

agerelated macular degeneration Salman Sarwar Elizabeth Clearfield Mohamed Soliman Mohammed Sadiq Andrew Baldwin Mostafa Hanout Aniruddha Agarwal Yasir Sepah Diana Do Quan Nguyen Issue 2 2016. Current understanding and . approaches to treatment. Prescribing information can be found on the last two slides. About this slide deck. This slide deck is provided as a service to medicine by Bayer and is intended for educational use with healthcare professionals . H. 6788. N. 1164. O. 1304. S. 32 . (115 . kDa. -with glycosylation). Eylea. . Regeneron. Pharmaceuticals. Zaltrap. . Regeneron. Pharmaceuticals. CATEGORY. . . Antineoplastic Agents. . Charles C. Wykoff, MD, PhD, FACS. Physician, Retina . Consultants of Houston. Blanton Eye Institute & . Houston Methodist Hospital. Houston, USA. Faculty. Scope of the Problem. 1st WHO Global Report: 1/12 . Comparative Effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for DME. Supported through a cooperative agreement from the . National Eye Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health, Department of Health and Human Services EY14231, EY14229, EY018817 . 1–2 1 InitiallystudiesofVEGFhaveprimarilycentredonitsroleintheprogressionofmalignancies.SeveraltreatmentsspecificallydesignedtoinhibitVEGFactivityhavebeenapprovedforthetreatmentincertaintypesofc 1. Disclosures. Supported by the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases under award numbers UG1EY014231 and UG1EY023207. . Regeneron provided aflibercept for the study and funds to the DRCR Retina Network to defray the study’s clinical site costs..